Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILENYA vs SODIUM THIOSULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.
Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
FDA-approved: Acute cyanide poisoning (in combination with sodium nitrite),Off-label: Reduction of nephrotoxicity from cisplatin chemotherapy,Off-label: Calciphylaxis (calcium uremic arteriolopathy),Off-label: Treatment of extravasation of vesicant drugs
0.5 mg orally once daily, with or without food
12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.
The terminal elimination half-life of fingolimod is approximately 6–9 days (mean 8.4 days). Due to the prolonged half-life, steady-state is achieved after 1–2 months of daily dosing, and lymphopenia may persist for up to 2 months after treatment cessation.
Terminal elimination half-life: 0.65 hours (IV in cyanide poisoning); context: rapid redistribution and excretion, requiring repeated doses.
Primarily metabolized by CYP4F2, and to a lesser extent by CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Extensive first-pass metabolism via reversible stereoselective phosphorylation to active metabolite fingolimod-phosphate; also undergoes oxidative metabolism. Elimination half-life is approximately 6-9 days.
Sodium thiosulfate is metabolized via the enzyme rhodanese (in liver and other tissues) to thiocyanate, which is then excreted renally. It also undergoes oxidation to sulfate.
Fingolimod is primarily eliminated via fecal excretion (81%) and to a lesser extent via renal excretion (<1% as unchanged drug). Biliary excretion accounts for a minor portion. The major metabolic pathway is via CYP4F2-mediated hydroxylation, followed by glucuronidation and elimination in feces.
Renal: >90% unchanged; minor biliary/fecal.
Fingolimod is approximately 99.7% bound to plasma proteins, primarily to albumin and lipoproteins (including α1-acid glycoprotein). The main active metabolite, fingolimod-phosphate, is also highly bound (>99%).
<5%; primarily albumin.
The volume of distribution (Vd) is approximately 17 L/kg (range 7–30 L/kg), indicating extensive tissue distribution, especially into erythrocytes (about 20% of total drug in blood) and sequestration in central nervous system and lymphoid tissues.
0.2-0.3 L/kg; indicates primarily extracellular distribution.
Oral bioavailability is approximately 93% (range 84–98%). Absorption is not significantly affected by food, but to reduce the risk of bradycardia and atrioventricular block, the first dose should be taken in the morning after a low-fat or fat-free meal.
Oral: approximately 0% (poorly absorbed, degraded in stomach); IV: 100%.
No dose adjustment required for mild to severe renal impairment including dialysis; monitor patients with severe renal impairment for bradycardia at treatment initiation
No dose adjustment required for GFR >30 m L/min; for GFR ≤30 m L/min, consider reducing dose by 50% or extending interval to every 12 hours due to possible thiosulfate accumulation.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh class A and B) but initiate with caution and monitor liver enzymes
No specific recommendations for Child-Pugh; use with caution in severe hepatic impairment due to potential metabolic and elimination effects.
Approved for pediatric patients aged 10 years and older: for body weight ≤40 kg, 0.25 mg orally once daily; for body weight >40 kg, standard adult dose of 0.5 mg orally once daily
For cyanide poisoning: 412.5 mg/kg (1.65 m L/kg of 25% solution) intravenously over 10 minutes; for methemoglobinemia: 1 mg/kg intravenously over 10 minutes.
No specific dose adjustment recommended; use with caution due to potential for decreased renal function and increased sensitivity to bradycardia, monitor heart rate and blood pressure
No specific dose adjustments; monitor renal function and volume status due to sodium load and potential reduced clearance.
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for at least 6 hours, including hourly pulse and blood pressure measurement, and ECG before and after first dose. Risk of infections, including fatal cryptococcal infections and other opportunistic infections. Risk of macular edema, especially in patients with uveitis or diabetes mellitus. Risk of posterior reversible encephalopathy syndrome (PRES). Risk of cutaneous malignancies (basal cell carcinoma, melanoma, Merkel cell carcinoma). Risk of fetal harm; advise females of reproductive potential of potential risk and need for effective contraception.
None.
Bradyarrhythmia: First-dose monitoring required; avoid in patients with sinoatrial block, sick sinus syndrome, second-degree or third-degree AV block unless pacemaker present.,Infections: Monitor for infections; consider suspending treatment if serious infection occurs. Vaccination against varicella zoster virus recommended before initiation.,Macular edema: Ophthalmologic evaluation before and 3-4 months after starting treatment; more frequent assessments in patients with diabetes or uveitis.,Respiratory effects: Dose-dependent decrease in forced expiratory volume and diffusion capacity; monitor pulmonary function if clinically indicated.,Elevated liver enzymes: Monitor liver enzymes before and during treatment; discontinue if significant liver injury occurs.,Fetal harm: Effective contraception required during and for 2 months after discontinuation.,Cutaneous malignancies: Baseline and routine dermatologic evaluations recommended.,Immune system effects: Avoid live attenuated vaccines during and for 2 months after treatment.,Posterior reversible encephalopathy syndrome (PRES): Evaluate rapidly if symptoms such as severe headache, altered mental status, visual disturbances, or seizures occur.,Increased blood pressure: Monitor blood pressure.,Reactivation of hepatitis B virus in carriers: Screen before initiation.,Tumor risk: Overall increased risk of malignancies, especially skin cancers and lymphomas.
Hypotension and increased anion gap metabolic acidosis (especially with high doses or rapid infusion),Hypocalcemia due to calcium chelation; monitor calcium levels,Thiocyanate accumulation, particularly in renal impairment; can lead to toxicity (e.g., nausea, disorientation, psychosis, muscle cramps),Hydration status should be monitored to avoid volume overload,Hypersensitivity reactions may occur
Hypersensitivity to fingolimod or any excipient,Recent myocardial infarction (within last 6 months),Unstable angina,Stroke or transient ischemic attack (within last 6 months),History of second-degree Mobitz type II or third-degree AV block, sick sinus syndrome, or sinoatrial block unless patient has an implanted pacemaker,Baseline QTc interval ≥500 msec,Treatment with Class Ia or Class III antiarrhythmics,Severe untreated sleep apnea,Concomitant use of pimozide
Known hypersensitivity to sodium thiosulfate or any component,Relative: Severe renal impairment (risk of thiocyanate toxicity)
No significant food interactions reported; take with or without food. Avoid grapefruit juice? No known interaction.
No known food interactions. Maintain adequate hydration unless contraindicated by renal status.
FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at doses similar to human exposure). Second and third trimesters: limited human data; animal studies show reduced fetal weight and increased fetal mortality. Risk cannot be excluded; use only if benefit outweighs risk.
Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide poisoning during pregnancy when benefit outweighs risk.
Not recommended during breastfeeding. Fingolimod is excreted in animal milk; unknown if excreted in human milk. M/P ratio not established. Potential for serious adverse reactions in nursing infants, including bradycardia, infections, and immunosuppression.
Sodium thiosulfate is excreted into breast milk in small amounts; M/P ratio is not established. It is considered compatible with breastfeeding, but caution is advised due to limited data.
No established dose adjustment in pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, decreased protein binding) may reduce exposure; consider therapeutic drug monitoring if available. Discontinue if pregnancy occurs unless benefit clearly outweighs risk.
No dosage adjustment is recommended for pregnancy. Pharmacokinetic changes in pregnancy are not well studied; standard weight-based dosing for cyanide poisoning should be used.
GILENYA (fingolimod) requires first-dose monitoring for 6 hours due to risk of bradyarrhythmia; obtain baseline ECG, CBC, LFTs, and ophthalmologic exam. Avoid in patients with recent MI, unstable angina, stroke, or certain arrhythmias. Monitor for infections, especially cryptococcal meningitis and PML. Rebound disease activity may occur upon discontinuation. Lymphopenia is expected; monitor lymphocyte counts regularly.
Sodium thiosulfate is used as an antidote for cyanide poisoning and for calciphylaxis. In cyanide poisoning, administer IV with sodium nitrite; monitor for hypotension and methemoglobinemia. For calciphylaxis, use after hemodialysis to prevent hypernatremia. Can cause prolonged QT interval, so monitor ECG. Do not mix with other drugs in IV line; incompatible with cisplatin.
Take exactly as prescribed; do not skip doses without consulting your doctor.,You will need a 6-hour observation period after the first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) or visual changes immediately.,Do not receive live vaccines while taking this medication.,Use effective contraception during treatment and for 2 months after stopping, as it may harm a fetus.
This medication is given intravenously to treat cyanide poisoning or a skin condition called calciphylaxis.,You may experience side effects such as nausea, vomiting, headache, or a metallic taste.,Your blood pressure, heart rhythm, and blood levels will be monitored during treatment.,Tell your doctor if you have heart problems, kidney disease, or low sodium levels.,Do not drink alcohol while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILENYA vs SODIUM THIOSULFATE, answered by our medical review team.
GILENYA is a Sphingosine 1-Phosphate Receptor Modulator that works by Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.. SODIUM THIOSULFATE is a Cyanide Antidote that works by Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILENYA and SODIUM THIOSULFATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILENYA is: 0.5 mg orally once daily, with or without food. The standard adult dose of SODIUM THIOSULFATE is: 12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILENYA and SODIUM THIOSULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILENYA is classified as Category C. FDA Pregnancy Category C. First trimester: potential for fetal harm based on animal studies (increased incidence of fetal malformations, including ventricular septal defects, at do. SODIUM THIOSULFATE is classified as Category C. Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.